Pancreas Transplantation from Donors after Circulatory Death: an Irrational Reluctance?
AbstractPurpose of ReviewBeta-cell replacement is the best therapeutic option for patients with type 1 diabetes. Because of donor scarcity, more extended criteria donors are used for transplantation. Donation after circulatory death donors (DCD) are not commonly used for pancreas transplantation, because of the supposed higher risk of complications. This review gives an overview on the pathophysiology, risk factors, and outcome in DCD transplantation and discusses different preservation methods.Recent FindingsStudies on outcomes of DCD pancreata show similar results compared with those of donation after brain death (DBD), when accumulation of other risk factors is avoided. Hypothermic machine perfusion is shown to be a safe method to improve graft viability in experimental settings.SummaryDCD should not be the sole reason to decline a pancreas for transplantation. Adequate donor selection and improved preservation techniques can lead to enhanced pancreas utilization and outcome.
Spouses Nan and Rex Vint in Indiana both live with type 1 diabetes, and have their own lingo and tactics for keeping their technology straight.
One of the more unexpected recent findings relating to cellular senescence is that it appears to be an important part of the mechanisms that lead to loss of the pancreatic β-cells responsible for insulin secretion in both type 1 diabetes and type 2 diabetes - which are very different conditions, despite the shared name. The authors of the brief open access commentary noted here discuss the present state of this research. Age is one of the major risk factors for the development of type 2 diabetes mellitus (T2D). However, the understanding of how cellular aging contributes to diabetes pathogenesis is incomplete...
CONCLUSIONS: T1DM girls revealed a decreased ratio of cortical bone area/muscle area, reflecting disturbed adaptation of the cortical shaft to the muscle force. When the Z-scores of cortical shell dimensions were investigated, cases in Tanner stage 5 diverged from "less mature" individuals, which may suggests that bone shaft development in these individuals was impaired, affecting both size and strength. PMID: 31789294 [PubMed - in process]
The Miami-based Diabetes Research Institute focused on finding a cure for type 1 diabetes has been supported by BioRep Technologies for 25 years.
Background: Fasting during Ramadan is a form of intermittent fasting in which a person abstains from oral intake between the hours of sunrise and sunset. The fasting month of Ramadan is observed by Muslims worldwide. People with type 1 diabetes (T1DM) who choose to fast during Ramadan are at a particularly high risk of acute diabetes complications including hypoglycemia and significant hyperglycemia. We hypothesized that people with uncomplicated T1DM would be able to fast safely during Ramadan following structured education and with daily advanced glucose monitoring.Methods: People with stable and uncomplicated T1DM treat...
Publication date: 3 December 2019Source: Cell Reports, Volume 29, Issue 10Author(s): Ashley E. Ciecko, Bardees Foda, Jennifer Y. Barr, Sheela Ramanathan, Mark A. Atkinson, David V. Serreze, Aron M. Geurts, Scott M. Lieberman, Yi-Guang ChenSummaryHuman genetic studies implicate interleukin-27 (IL-27) in the pathogenesis of type 1 diabetes (T1D), but the underlying mechanisms remain largely unexplored. To further define the role of IL-27 in T1D, we generated non-obese diabetic (NOD) mice deficient in IL-27 or IL-27Rα. In contrast to wild-type NOD mice, both NOD.Il27−/− and NOD.Il27ra−/− strains ...
CONCLUSION: JIA appears to be associated with an increased risk of T1D compared to asthma and healthy children. PMID: 31787600 [PubMed - as supplied by publisher]
Condition: Diabetes Mellitus, Type 1 Intervention: Sponsor: Tampere University Hospital Not yet recruiting
The company now wants to accelerate the commercial rollout of a system for management of Type 1 diabetes.
Funding Opportunity RFA-DK-19-036 from the NIH Guide for Grants and Contracts. This FOA will support the conduct of clinical trials designed to test the clinical safety and efficacy of artificial pancreas (AP) device systems with the objective of improving glycemic control, reducing acute complications and improving quality of life in people with difficult to control T1D when using standard of care therapies.